Elderly patients (65 years or older at the time of first administration) with type 2 diabetes who used Suglat Tablets within 3 months from its launch are included in this study. Followings are measured with the patients.~Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors.~Investigate the occurrence of urinary tract infection.~Investigate the occurrence of adverse drug reactions in patients at a high risk (those who have poorly controlled blood sugar levels, concurrent organic abnormalities in the urinary system, advanced diabetic neuropathy, etc).~Investigate the occurrence of adverse drug reactions other than the above.~Factors that may possibly influence the safety of Suglat Tablets.
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.